COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
FinanceWire intègre Certidox pour permettre la vérification des communiqués de presse, alors que les contenus falsifiés deviennent impossibles à distinguer de la réalité
FinanceWire intègre Certidox pour sécuriser la vérification des communiqués de presse et empêcher la falsification, garantissant l'authenticité des contenus diffusés sur des médias tels que Yahoo Finance et MarketWatch -
-
COMMUNIQUÉ DE PRESSE
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 4.803 Million Tokens, and Total Crypto and Total Cash Holdings of $11.4 Billion
Bitmine Immersion Technologies (BMNR) announces ETH holdings reach 4.803 million tokens and total crypto and total cash holdings of $11.4 billion. Bitmine approved for uplisting to NYSE from NYSE American -
COMMUNIQUÉ DE PRESSE
Black Iron annonce un placement privé d’unités pour un produit brut pouvant atteindre 1,7 million de dollars américains
Black Iron Inc. annonce un placement privé sans courtier pour un produit brut d'environ 1,7 M$ US. Les unités seront offertes aux acheteurs canadiens. Consultez le document d'offre sur SEDAR+ et le site Web -
COMMUNIQUÉ DE PRESSE
DeFi Technologies Announces Shareholder Call to Discuss Record 2025 Financial Results with Revenue of $99.1 Million and Net Income of $62.7 Million
DeFi Technologies announces record 2025 financial results with $99.1M revenue and $62.7M net income. Shareholder call scheduled for April 7, 2026, to discuss performance -
-
COMMUNIQUÉ DE PRESSE
Revolve Signs Interconnection Agreement for 130 MW EL 24 Wind Project in Mexico
Revolve Renewable Power announces final interconnection agreement with CFE for 130MW wind project in Mexico, reaching key development milestone. Company focuses on project optimization and commercial strategies -
-
COMMUNIQUÉ DE PRESSE
K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Kowa Company Ltd. to present non-clinical data for novel antibody drug-loaded unimicelle conjugate K-679 at AACR Annual Meeting 2026 showcasing tumor-selective pharmacokinetics
